SEATTLE--(BUSINESS WIRE)--Amkor Pharmaceuticals, Inc. today reports that all clinical activities of its Phase I, double-blinded, randomized, placebo-controlled ascending intravenous (IV) single dose (both loading and maintenance infusion) study assessing the safety, tolerance, and pharmacokinetics (PK) of Neu2000KL in 95 healthy young and elderly volunteers has been completed.
